134 related articles for article (PubMed ID: 38639400)
1. AJICAP-M: Traceless Affinity Peptide Mediated Conjugation Technology for Site-Selective Antibody-Drug Conjugate Synthesis.
Matsuda Y; Shikida N; Hatada N; Yamada K; Seki T; Nakahara Y; Endo Y; Shimbo K; Takahashi K; Nakayama A; Mendelsohn BA; Fujii T; Okuzumi T; Hirasawa S
Org Lett; 2024 Apr; ():. PubMed ID: 38639400
[TBL] [Abstract][Full Text] [Related]
2. AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production.
Fujii T; Matsuda Y; Seki T; Shikida N; Iwai Y; Ooba Y; Takahashi K; Isokawa M; Kawaguchi S; Hatada N; Watanabe T; Takasugi R; Nakayama A; Shimbo K; Mendelsohn BA; Okuzumi T; Yamada K
Bioconjug Chem; 2023 Mar; 34(4):728-38. PubMed ID: 36894324
[TBL] [Abstract][Full Text] [Related]
3. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T
Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528
[TBL] [Abstract][Full Text] [Related]
4. Good Manufacturing Practice Strategy for Antibody-Drug Conjugate Synthesis Using Site-Specific Chemical Conjugation: First-Generation AJICAP.
Matsuda Y; Clancy C; Tawfiq Z; Robles V; Mendelsohn BA
ACS Omega; 2019 Dec; 4(24):20564-20570. PubMed ID: 31858041
[TBL] [Abstract][Full Text] [Related]
5. Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation.
Matsuda Y; Malinao MC; Robles V; Song J; Yamada K; Mendelsohn BA
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Mar; 1140():121981. PubMed ID: 32036254
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Analytical Methods for Antibody-Drug Conjugates Produced by Chemical Site-Specific Conjugation: First-Generation AJICAP.
Matsuda Y; Robles V; Malinao MC; Song J; Mendelsohn BA
Anal Chem; 2019 Oct; 91(20):12724-12732. PubMed ID: 31478640
[TBL] [Abstract][Full Text] [Related]
7. Chromatographic analysis of site-specific antibody-drug conjugates produced by AJICAP first-generation technology using a recombinant FcγIIIa receptor-ligand affinity column.
Matsuda Y; Chakrabarti A; Takahashi K; Yamada K; Nakata K; Okuzumi T; Mendelsohn BA
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jul; 1177():122753. PubMed ID: 34098178
[TBL] [Abstract][Full Text] [Related]
8. Biological Evaluation of Maytansinoid-Based Site-Specific Antibody-Drug Conjugate Produced by Fully Chemical Conjugation Approach: AJICAP®.
Seki T; Yamada K; Ooba Y; Fujii T; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Matsuda Y; Okuzumi T
Front Biosci (Landmark Ed); 2022 Aug; 27(8):234. PubMed ID: 36042175
[TBL] [Abstract][Full Text] [Related]
9. Application of Native Ion Exchange Mass Spectrometry to Intact and Subunit Analysis of Site-Specific Antibody-Drug Conjugates Produced by AJICAP First Generation Technology.
Matsuda Y; Kliman M; Mendelsohn BA
J Am Soc Mass Spectrom; 2020 Jul; ():. PubMed ID: 32608232
[TBL] [Abstract][Full Text] [Related]
10. AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies.
Yamada K; Shikida N; Shimbo K; Ito Y; Khedri Z; Matsuda Y; Mendelsohn BA
Angew Chem Int Ed Engl; 2019 Apr; 58(17):5592-5597. PubMed ID: 30854738
[TBL] [Abstract][Full Text] [Related]
11. Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second-Generation.
Fujii T; Ito K; Takahashi K; Aoki T; Takasugi R; Seki T; Iwai Y; Watanabe T; Hirama R; Tsumura R; Fuchigami H; Yasunaga M; Matsuda Y
ACS Med Chem Lett; 2023 Dec; 14(12):1767-1773. PubMed ID: 38116449
[TBL] [Abstract][Full Text] [Related]
12. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
13. An overview of process development for antibody-drug conjugates produced by chemical conjugation technology.
Matsuda Y; Mendelsohn BA
Expert Opin Biol Ther; 2021 Jul; 21(7):963-975. PubMed ID: 33141625
[No Abstract] [Full Text] [Related]
14. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
15. A Traceless Site-Specific Conjugation on Native Antibodies Enables Efficient One-Step Payload Assembly.
Zeng Y; Shi W; Dong Q; Li W; Zhang J; Ren X; Tang C; Liu B; Song Y; Wu Y; Diao X; Zhou H; Huang H; Tang F; Huang W
Angew Chem Int Ed Engl; 2022 Sep; 61(36):e202204132. PubMed ID: 35737596
[TBL] [Abstract][Full Text] [Related]
16. Photoconjugation of an Fc-Specific Peptide Enables Efficient DAR 2 Antibody-Drug Conjugate Formation.
Lee T; Kim JH; Kwon SJ; Park SH; Kim J; Kang HJ; Chung SJ
Org Lett; 2020 Nov; 22(21):8419-8423. PubMed ID: 33074682
[TBL] [Abstract][Full Text] [Related]
17. Effect of Conjugation Site and Technique on the Stability and Pharmacokinetics of Antibody-Drug Conjugates.
Kaempffe A; Dickgiesser S; Rasche N; Paoletti A; Bertotti E; De Salve I; Sirtori FR; Kellner R; Könning D; Hecht S; Anderl J; Kolmar H; Schröter C
J Pharm Sci; 2021 Dec; 110(12):3776-3785. PubMed ID: 34363839
[TBL] [Abstract][Full Text] [Related]
18. State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis.
Deslignière E; Ehkirch A; Duivelshof BL; Toftevall H; Sjögren J; Guillarme D; D'Atri V; Beck A; Hernandez-Alba O; Cianférani S
Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073805
[TBL] [Abstract][Full Text] [Related]
19. Site-Specific Quantitation of Drug Conjugations on Antibody-Drug Conjugates (ADCs) Using a Protease-Assisted Drug Deconjugation and Linker-like Labeling (PADDLL) Method.
Yang X; Seol H; Lin W; Xu X; Shen B; Qiu H; Li N
Anal Chem; 2021 Jul; 93(27):9549-9558. PubMed ID: 34196532
[TBL] [Abstract][Full Text] [Related]
20. A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation.
Matsuda Y; Leung M; Okuzumi T; Mendelsohn B
Antibodies (Basel); 2020 May; 9(2):. PubMed ID: 32443479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
